Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABOR2014 (IPM511) in Advanced Hepatocellular Carcinoma
NCT05981066Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Vaccine mRNA, mRNA Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABOR2014 in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Incidence and severity of adverse events (AE) up to 12 months, Clinically significant abnormal changes in vital signs up to 12 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
ABOR2014
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05981066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981066.